$ICCT
iCoreConnect Inc.

2024 Q3 Form 10-Q Financial Statement

#000147793224005038 Filed on August 16, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $2.788M $3.088M
YoY Change 39.06% 66.36%
Cost Of Revenue $827.0K $606.6K
YoY Change 59.69% 25.33%
Gross Profit $1.961M $2.481M
YoY Change 31.88% 80.84%
Gross Profit Margin 70.34% 80.36%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.161M $9.969M
YoY Change 6.43% 186.41%
Operating Profit -$2.200M -$7.488M
YoY Change -9.19% 866.78%
Interest Expense $223.1K $501.6K
YoY Change -53.38% -181.86%
% of Operating Profit
Other Income/Expense, Net -$3.790M $0.00
YoY Change 198.77% -100.0%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$5.991M -$10.90M
YoY Change 53.2% -66116.81%
Net Earnings / Revenue -214.88% -352.84%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 10.40M shares 10.15M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $212.3K $247.2K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $798.3K $703.8K
Other Receivables
Total Short-Term Assets $1.452M $1.443M
YoY Change -28.08% 978.63%
LONG-TERM ASSETS
Property, Plant & Equipment $179.1K $183.6K
YoY Change -10.63% -82.56%
Goodwill $1.485M $1.485M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $12.77M $15.99M
YoY Change -11.24% -81.35%
TOTAL ASSETS
Total Short-Term Assets $1.452M $1.443M
Total Long-Term Assets $12.77M $15.99M
Total Assets $14.22M $17.43M
YoY Change -13.31% -79.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $6.953M $6.544M
YoY Change 88.16% -5.29%
Total Short-Term Liabilities $13.12M $12.94M
YoY Change 45.84% 474.18%
LONG-TERM LIABILITIES
Long-Term Debt $3.138M $2.943M
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.119M $4.081M
YoY Change 310.94% 440.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.12M $12.94M
Total Long-Term Liabilities $4.119M $4.081M
Total Liabilities $17.24M $17.02M
YoY Change 72.41% 655.28%
SHAREHOLDERS EQUITY
Retained Earnings -$138.2M -$131.6M
YoY Change 28.66% 6105.12%
Common Stock $1.184K $1.040K
YoY Change 41.29% 392.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.021M $410.6K
YoY Change
Total Liabilities & Shareholders Equity $14.22M $17.43M
YoY Change -13.31% -79.7%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$5.991M -$10.90M
YoY Change 53.2% -66116.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
563905 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
492280 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1725062 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1443225 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3508325 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
183637 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
202421 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
996285 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1122412 usd
CY2024Q2 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
1126733 usd
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
903412 usd
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
6435973 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
0 usd
CY2023Q4 us-gaap Assets
Assets
15686504 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4720454 usd
CY2023Q4 icct Related Party Notes Payable Current
RelatedPartyNotesPayableCurrent
550975 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8876310 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1420137 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
945889 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2366026 usd
CY2023Q4 us-gaap Liabilities
Liabilities
11242336 usd
us-gaap Other Expenses
OtherExpenses
54000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1219358 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
196153 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247194 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68735 usd
us-gaap Interest Paid Net
InterestPaidNet
132566 usd
us-gaap Interest Paid Net
InterestPaidNet
348941 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001906133
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10404336 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247194 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4376709 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3755209 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10404336 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10068477 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
icct Warrants To Be Issued Additional
WarrantsToBeIssuedAdditional
0 shares
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
540000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41309
dei Entity Registrant Name
EntityRegistrantName
iCoreConnect Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2462502
dei Entity Address Address Line1
EntityAddressAddressLine1
529 E. Crown Point Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
Ocoee
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34761
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
810-7706
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ICCT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10404336 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247194 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1219358 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
703751 usd
CY2024Q2 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
2439379 usd
CY2024Q2 icct Forward Purchase Agreement Amount
ForwardPurchaseAgreementAmount
3321883 usd
CY2023Q4 icct Forward Purchase Agreement Amount
ForwardPurchaseAgreementAmount
5484556 usd
CY2024Q2 us-gaap Goodwill
Goodwill
1484966 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
15988856 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
12178179 usd
CY2024Q2 us-gaap Assets
Assets
17432081 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5735108 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3243338 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
239428 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
6543511 usd
CY2024Q2 icct Related Party Notes Payable Current
RelatedPartyNotesPayableCurrent
279462 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
142528 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
119598 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1219358 usd
CY2024Q2 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
2439379 usd
CY2023Q4 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
2980412 usd
CY2024Q2 icct Forward Purchase Agreement Amount
ForwardPurchaseAgreementAmount
3321883 usd
CY2023Q4 icct Forward Purchase Agreement Amount
ForwardPurchaseAgreementAmount
5484556 usd
CY2023Q4 us-gaap Goodwill
Goodwill
1484966 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
15988856 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
12178179 usd
CY2024Q2 us-gaap Assets
Assets
17432081 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5735108 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
239428 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
241945 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
6543511 usd
CY2024Q2 icct Related Party Notes Payable Current
RelatedPartyNotesPayableCurrent
279462 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
142528 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
119598 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12940037 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2942584 usd
CY2024Q2 icct Long Term Related Party Debt Net Of Current Maturities
LongTermRelatedPartyDebtNetOfCurrentMaturities
314469 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
824342 usd
CY2024Q2 us-gaap Liabilities
Liabilities
17021432 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4376709 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3755209 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
438 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
376 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10404336 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10068477 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1040 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1007 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131962312 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119481543 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131553141 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115038758 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
410649 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4444168 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17432081 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15686504 usd
CY2024Q2 us-gaap Revenues
Revenues
3087900 usd
CY2023Q2 us-gaap Revenues
Revenues
1856148 usd
us-gaap Revenues
Revenues
5811263 usd
us-gaap Revenues
Revenues
3696519 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
606617 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
484033 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1119714 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
975482 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
2481283 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
1372115 usd
us-gaap Gross Profit
GrossProfit
4691549 usd
us-gaap Gross Profit
GrossProfit
2721037 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9187200 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12940037 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2942584 usd
CY2024Q2 icct Long Term Related Party Debt Net Of Current Maturities
LongTermRelatedPartyDebtNetOfCurrentMaturities
314469 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
824342 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4081395 usd
CY2024Q2 us-gaap Liabilities
Liabilities
17021432 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4376709 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3755209 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
438 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
376 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10404336 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10068477 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1040 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1007 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131962312 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119481543 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131553141 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115038758 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
410649 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4444168 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17432081 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15686504 usd
CY2024Q2 us-gaap Revenues
Revenues
3087900 usd
CY2023Q2 us-gaap Revenues
Revenues
1856148 usd
us-gaap Revenues
Revenues
5811263 usd
us-gaap Revenues
Revenues
3696519 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
606617 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
484033 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1119714 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
975482 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
2481283 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
1372115 usd
us-gaap Gross Profit
GrossProfit
4691549 usd
us-gaap Gross Profit
GrossProfit
2721037 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9187200 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3189103 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13707098 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5600174 usd
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
781890 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
291600 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1514443 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
580509 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
9969090 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3480703 usd
us-gaap Operating Expenses
OperatingExpenses
15221541 usd
us-gaap Operating Expenses
OperatingExpenses
6180683 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7487807 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2108588 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10529992 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3459646 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3189103 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13707098 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5600174 usd
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
781890 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
291600 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1514443 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
580509 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
9969090 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3480703 usd
us-gaap Operating Expenses
OperatingExpenses
15221541 usd
us-gaap Operating Expenses
OperatingExpenses
6180683 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7487807 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2108588 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10529992 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3459646 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
501646 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
270770 usd
us-gaap Interest Expense
InterestExpense
728111 usd
us-gaap Interest Expense
InterestExpense
528683 usd
CY2024Q2 us-gaap Financing Interest Expense
FinancingInterestExpense
443288 usd
CY2023Q2 us-gaap Financing Interest Expense
FinancingInterestExpense
342015 usd
us-gaap Financing Interest Expense
FinancingInterestExpense
2143607 usd
us-gaap Financing Interest Expense
FinancingInterestExpense
422078 usd
CY2024Q2 icct Change In Fair Value Of Forward Purchase Agreement
ChangeInFairValueOfForwardPurchaseAgreement
-2462673 usd
CY2023Q2 icct Change In Fair Value Of Forward Purchase Agreement
ChangeInFairValueOfForwardPurchaseAgreement
0 usd
icct Change In Fair Value Of Forward Purchase Agreement
ChangeInFairValueOfForwardPurchaseAgreement
0 usd
CY2024Q2 us-gaap Other Expenses
OtherExpenses
0 usd
us-gaap Other Expenses
OtherExpenses
0 usd
CY2024Q2 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0 usd
CY2023Q2 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
13778 usd
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0 usd
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
13778 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3407607 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-599007 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5088391 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-936983 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10895414 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2707595 usd
us-gaap Net Income Loss
NetIncomeLoss
-15618383 usd
us-gaap Net Income Loss
NetIncomeLoss
-4396629 usd
CY2024Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
447999 usd
CY2023Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
895999 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11343413 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2707595 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16514382 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4396629 usd
CY2024Q2 icct Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-1.10
CY2023Q2 icct Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.41
icct Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-1.62
icct Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.68
CY2024Q2 icct Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
10272141 shares
CY2023Q2 icct Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
6567612 shares
icct Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
10186284 shares
CY2024Q2 us-gaap Interest Expense
InterestExpense
501646 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
270770 usd
us-gaap Interest Expense
InterestExpense
728111 usd
us-gaap Interest Expense
InterestExpense
528683 usd
CY2024Q2 us-gaap Financing Interest Expense
FinancingInterestExpense
443288 usd
CY2023Q2 us-gaap Financing Interest Expense
FinancingInterestExpense
342015 usd
us-gaap Financing Interest Expense
FinancingInterestExpense
2143607 usd
us-gaap Financing Interest Expense
FinancingInterestExpense
422078 usd
CY2024Q2 icct Change In Fair Value Of Forward Purchase Agreement
ChangeInFairValueOfForwardPurchaseAgreement
-2462673 usd
CY2023Q2 icct Change In Fair Value Of Forward Purchase Agreement
ChangeInFairValueOfForwardPurchaseAgreement
0 usd
icct Change In Fair Value Of Forward Purchase Agreement
ChangeInFairValueOfForwardPurchaseAgreement
-2162673 usd
CY2024Q2 us-gaap Other Expenses
OtherExpenses
0 usd
us-gaap Other Expenses
OtherExpenses
0 usd
CY2024Q2 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0 usd
CY2023Q2 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
13778 usd
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0 usd
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
13778 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3407607 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-599007 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5088391 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-936983 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10895414 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2707595 usd
us-gaap Net Income Loss
NetIncomeLoss
-15618383 usd
us-gaap Net Income Loss
NetIncomeLoss
-4396629 usd
CY2024Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
447999 usd
CY2023Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
895999 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11343413 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2707595 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16514382 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4396629 usd
CY2024Q2 icct Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-1.10
CY2023Q2 icct Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.41
icct Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-1.62
icct Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.68
CY2024Q2 icct Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
10272141 shares
CY2023Q2 icct Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
6567612 shares
icct Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
10186284 shares
icct Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
6481840 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4444168 usd
CY2024Q1 icct Origination Fee In Convertible Debt Agreement Amount
OriginationFeeInConvertibleDebtAgreementAmount
182004 usd
CY2024Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
840000 usd
CY2024Q1 icct Stock Issued For Purchase Of Featherpay Amount
StockIssuedForPurchaseOfFeatherpayAmount
4800000 usd
CY2024Q1 icct Stock Issued For The Purchase Of Teamworx Amount
StockIssuedForThePurchaseOfTeamworxAmount
575000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
507679 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-5170970 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6177880 usd
CY2024Q2 icct Origination Fee In Convertible Debt Agreement Amount
OriginationFeeInConvertibleDebtAgreementAmount
298324 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5277856 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-11343413 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
410649 usd
us-gaap Net Income Loss
NetIncomeLoss
-15618383 usd
icct Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
6481840 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4444168 usd
CY2024Q1 icct Origination Fee In Convertible Debt Agreement Amount
OriginationFeeInConvertibleDebtAgreementAmount
182004 usd
CY2024Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
840000 usd
CY2024Q1 icct Stock Issued For Purchase Of Featherpay Amount
StockIssuedForPurchaseOfFeatherpayAmount
4800000 usd
CY2024Q1 icct Stock Issued For The Purchase Of Teamworx Amount
StockIssuedForThePurchaseOfTeamworxAmount
575000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
507679 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-5170970 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6177880 usd
CY2024Q2 icct Origination Fee In Convertible Debt Agreement Amount
OriginationFeeInConvertibleDebtAgreementAmount
298324 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5277856 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-11343413 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
410649 usd
us-gaap Net Income Loss
NetIncomeLoss
-15618383 usd
us-gaap Net Income Loss
NetIncomeLoss
-4396629 usd
us-gaap Depreciation
Depreciation
18784 usd
us-gaap Depreciation
Depreciation
10577 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1495659 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
569932 usd
icct Finance Fee
FinanceFee
1745985 usd
icct Finance Fee
FinanceFee
422078 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
123797 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
110520 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5785528 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1024144 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
626572 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
103539 usd
icct Change In Fair Value Of Forward Purchase Agreements
ChangeInFairValueOfForwardPurchaseAgreements
-2162673 usd
icct Change In Fair Value Of Forward Purchase Agreements
ChangeInFairValueOfForwardPurchaseAgreements
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-13778 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
208425 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
61651 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1232782 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
203949 usd
icct Increase Decrease In Right Of Use Asset Net Of Lease Liability
IncreaseDecreaseInRightOfUseAssetNetOfLeaseLiability
-2063 usd
icct Increase Decrease In Right Of Use Asset Net Of Lease Liability
IncreaseDecreaseInRightOfUseAssetNetOfLeaseLiability
-3961 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1595770 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
409777 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
28710 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
74293 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1008485 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1919630 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
370000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
500000 usd
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
28000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
178150 usd
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
465837 usd
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
359758 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1335837 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-509908 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2812001 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2263010 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
1439843 usd
us-gaap Net Income Loss
NetIncomeLoss
-4396629 usd
us-gaap Depreciation
Depreciation
18784 usd
us-gaap Depreciation
Depreciation
10577 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1495659 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
569932 usd
icct Finance Fee
FinanceFee
1745985 usd
icct Finance Fee
FinanceFee
422078 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
123797 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
110520 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5785528 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1024144 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
626572 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
103539 usd
icct Change In Fair Value Of Forward Purchase Agreements
ChangeInFairValueOfForwardPurchaseAgreements
-2162673 usd
icct Change In Fair Value Of Forward Purchase Agreements
ChangeInFairValueOfForwardPurchaseAgreements
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-13778 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
208425 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
61651 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1232782 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
203949 usd
icct Increase Decrease In Right Of Use Asset Net Of Lease Liability
IncreaseDecreaseInRightOfUseAssetNetOfLeaseLiability
-2063 usd
icct Increase Decrease In Right Of Use Asset Net Of Lease Liability
IncreaseDecreaseInRightOfUseAssetNetOfLeaseLiability
-3961 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1595770 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
409777 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
28710 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
74293 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1008485 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1919630 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
370000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
500000 usd
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
28000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
178150 usd
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
465837 usd
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
359758 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1335837 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-509908 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2812001 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2263010 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
1439843 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
1186223 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
540000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
685333 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2302120 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-972164 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-127418 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
62 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. NATURE OF OPERATIONS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">iCoreConnect Inc. (formerly known as FG Merger Corp) (collectively with its subsidiary, the “Company”), a Delaware Corporation, is a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise platform of applications and services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to August 25, 2023, the Company was a special purpose acquisition company formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On August 25, 2023 (the “Closing Date”), the Company consummated the business combination contemplated by the Merger Agreement and Plan of Reorganization by and among FG Merger Corp, a special purpose acquisition company incorporated in Delaware (“FGMC”), FG Merger Sub, Inc., a Nevada corporation and wholly owned subsidiary of FGMC (“Merger Sub”), and iCoreConnect Inc., a Nevada corporation(“iCore”), dated as of January 5, 2023 (“Merger Agreement”). Pursuant to the terms of the Merger Agreement, a business combination between FGMC and iCore. was affected through the merger of Merger Sub with and into iCore, with iCore. surviving the merger as a wholly owned subsidiary of FGMC. On the Closing Date, FGMC was renamed “iCoreConnect Inc.” and the previous iCoreConect Inc. was renamed “iCore Midco, Inc.” (“Old iCore”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Business Combinations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 1, 2024 the Company completed the acquisitions for substantial all the assets of (a)Ally Commerce, Inc. dba FeatherPay; (b) Verifi Dental, Limited; and (c) Teamworx LLC which are all accounted for as asset acquisitions. On September 1, 2023, the Company completed the acquisitions for substantially all of the assets of Preferred Dental Development, LLC which was accounted for as an asset acquisition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern and Liquidity</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the six months ended June 30, 2024, the Company generated an operating loss of $10,529,992. In addition, at June 30, 2024, the Company has an accumulated deficit, and net working capital deficit of $131,553,141 and $11,496,812 respectively. The Company’s activities were primarily financed through private placements of equity securities and issuance of debt. The Company intends to raise additional capital through the issuance of debt and/or equity securities to fund its operations. The Company is reliant on future fundraising to finance operations in the near future. Such financings may not be available on terms satisfactory to the Company, if at all. In light of these matters, there is substantial doubt that the Company will be able to continue as a going concern for a period of 12 months from the issuance date of these financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Currently, management intends to develop an improved healthcare communications system and intends to develop alliances with strategic partners to generate revenues that will sustain the Company. While management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. Management’s ability to continue as a going concern is ultimately dependent upon its ability to continually increase the Company’s customer base and realize increased revenues from signed contracts. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
us-gaap Operating Income Loss
OperatingIncomeLoss
-10529992 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131553141 usd
CY2024Q2 icct Working Capital Deficit
WorkingCapitalDeficit
-11496812 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
1186223 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
540000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
685333 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1372158 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-972164 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-127418 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
62 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. NATURE OF OPERATIONS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">iCoreConnect Inc. (formerly known as FG Merger Corp) (collectively with its subsidiary, the “Company”), a Delaware Corporation, is a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise platform of applications and services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to August 25, 2023, the Company was a special purpose acquisition company formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On August 25, 2023 (the “Closing Date”), the Company consummated the business combination contemplated by the Merger Agreement and Plan of Reorganization by and among FG Merger Corp, a special purpose acquisition company incorporated in Delaware (“FGMC”), FG Merger Sub, Inc., a Nevada corporation and wholly owned subsidiary of FGMC (“Merger Sub”), and iCoreConnect Inc., a Nevada corporation(“iCore”), dated as of January 5, 2023 (“Merger Agreement”). Pursuant to the terms of the Merger Agreement, a business combination between FGMC and iCore. was affected through the merger of Merger Sub with and into iCore, with iCore. surviving the merger as a wholly owned subsidiary of FGMC. On the Closing Date, FGMC was renamed “iCoreConnect Inc.” and the previous iCoreConect Inc. was renamed “iCore Midco, Inc.” (“Old iCore”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Business Combinations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 1, 2024 the Company completed the acquisitions for substantial all the assets of (a)Ally Commerce, Inc. dba FeatherPay; (b) Verifi Dental, Limited; and (c) Teamworx LLC which are all accounted for as asset acquisitions. On September 1, 2023, the Company completed the acquisitions for substantially all of the assets of Preferred Dental Development, LLC which was accounted for as an asset acquisition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern and Liquidity</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the six months ended June 30, 2024, the Company generated an operating loss of $10,529,992. In addition, at June 30, 2024, the Company has an accumulated deficit, and net working capital deficit of $131,553,141 and $11,496,812 respectively. The Company’s activities were primarily financed through private placements of equity securities and issuance of debt. The Company intends to raise additional capital through the issuance of debt and/or equity securities to fund its operations. The Company is reliant on future fundraising to finance operations in the near future. Such financings may not be available on terms satisfactory to the Company, if at all. In light of these matters, there is substantial doubt that the Company will be able to continue as a going concern for a period of 12 months from the issuance date of these financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Currently, management intends to develop an improved healthcare communications system and intends to develop alliances with strategic partners to generate revenues that will sustain the Company. While management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. Management’s ability to continue as a going concern is ultimately dependent upon its ability to continually increase the Company’s customer base and realize increased revenues from signed contracts. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
us-gaap Operating Income Loss
OperatingIncomeLoss
-10529992 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131553141 usd
CY2024Q2 icct Working Capital Deficit
WorkingCapitalDeficit
-11496812 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
44600 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
44600 usd
icct Recurring Revenues
RecurringRevenues
5415913 usd
icct Recurring Revenues
RecurringRevenues
3333814 usd
icct Non Recurring Revenues
NonRecurringRevenues
395350 usd
icct Non Recurring Revenues
NonRecurringRevenues
362705 usd
icct Recurring Revenues
RecurringRevenues
5415913 usd
icct Recurring Revenues
RecurringRevenues
3333814 usd
icct Non Recurring Revenues
NonRecurringRevenues
395350 usd
icct Non Recurring Revenues
NonRecurringRevenues
362705 usd
us-gaap Advertising Expense
AdvertisingExpense
398750 usd
us-gaap Advertising Expense
AdvertisingExpense
306468 usd
us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for derivative instruments in accordance with ASC 815 “Derivatives and Hedging”, which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms of convertible debt and preferred stock instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability.</p>
us-gaap Advertising Expense
AdvertisingExpense
398750 usd
us-gaap Advertising Expense
AdvertisingExpense
306468 usd
us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for derivative instruments in accordance with ASC 815 “Derivatives and Hedging”, which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms of convertible debt and preferred stock instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability.</p>
CY2023Q3 icct Capital Stock Authorized
CapitalStockAuthorized
140000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 icct Capital Stock Authorized
CapitalStockAuthorized
140000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
17002897 usd
CY2024Q2 us-gaap Secured Debt Repurchase Agreements
SecuredDebtRepurchaseAgreements
12569810 usd
CY2024Q2 icct Due From Officers Or Stockholders Or Related Party Current
DueFromOfficersOrStockholdersOrRelatedPartyCurrent
4433087 usd
CY2024Q2 us-gaap Sale Leaseback Transaction Historical Cost
SaleLeasebackTransactionHistoricalCost
4433087 usd
CY2024Q2 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
0 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
17002897 usd
CY2024Q2 us-gaap Secured Debt Repurchase Agreements
SecuredDebtRepurchaseAgreements
12569810 usd
CY2024Q2 icct Due From Officers Or Stockholders Or Related Party Current
DueFromOfficersOrStockholdersOrRelatedPartyCurrent
4433087 usd
CY2024Q2 us-gaap Sale Leaseback Transaction Historical Cost
SaleLeasebackTransactionHistoricalCost
4433087 usd
CY2024Q2 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
0 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
10541275 usd
CY2023 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
-105676 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-6551775 usd
CY2023Q4 icct Finite Lived Intangible Asset Net Carrying Amount
FiniteLivedIntangibleAssetNetCarryingAmount
3883824 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16522334 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-6520249 usd
CY2024Q2 icct Finite Lived Intangible Asset Net Carrying Amount
FiniteLivedIntangibleAssetNetCarryingAmount
10002085 usd
us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
1495660 usd
us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
569932 usd
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
100000 shares
icct Redemption Price Per Shares
RedemptionPricePerShares
10.69
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
10541275 usd
CY2023 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
-105676 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-6551775 usd
CY2023Q4 icct Finite Lived Intangible Asset Net Carrying Amount
FiniteLivedIntangibleAssetNetCarryingAmount
3883824 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16522334 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-6520249 usd
CY2024Q2 icct Finite Lived Intangible Asset Net Carrying Amount
FiniteLivedIntangibleAssetNetCarryingAmount
10002085 usd
us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
1495660 usd
us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
569932 usd
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
100000 shares
icct Redemption Price Per Shares
RedemptionPricePerShares
10.69
CY2024Q2 us-gaap Notes Payable
NotesPayable
10015865 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
6337429 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
161109 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 usd
CY2024Q2 us-gaap Financing Receivable Unamortized Loan Fee Cost
FinancingReceivableUnamortizedLoanFeeCost
368661 usd
CY2023Q4 us-gaap Financing Receivable Unamortized Loan Fee Cost
FinancingReceivableUnamortizedLoanFeeCost
196837 usd
CY2024Q2 icct Total Notes Payable Net Of Financing Costs
TotalNotesPayableNetOfFinancingCosts
9486095 usd
CY2023Q4 icct Total Notes Payable Net Of Financing Costs
TotalNotesPayableNetOfFinancingCosts
6140592 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
6543511 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4720455 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
2942584 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1420137 usd
CY2023Q3 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1200000 usd
CY2023Q3 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.12 pure
CY2023Q3 us-gaap Interest Expense
InterestExpense
38609 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Notes Payable
NotesPayable
10015865 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
6337429 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
161109 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 usd
CY2024Q2 us-gaap Financing Receivable Unamortized Loan Fee Cost
FinancingReceivableUnamortizedLoanFeeCost
368661 usd
CY2023Q4 us-gaap Financing Receivable Unamortized Loan Fee Cost
FinancingReceivableUnamortizedLoanFeeCost
196837 usd
CY2024Q2 icct Total Notes Payable Net Of Financing Costs
TotalNotesPayableNetOfFinancingCosts
9486095 usd
CY2023Q4 icct Total Notes Payable Net Of Financing Costs
TotalNotesPayableNetOfFinancingCosts
6140592 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
6543511 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4720455 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
2942584 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1420137 usd
CY2023Q3 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1200000 usd
CY2023Q3 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.12 pure
CY2023Q3 us-gaap Interest Expense
InterestExpense
38609 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
102208 usd
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
233651 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
icct Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginning
776328 shares
icct Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning
3.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5100241 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.64
icct Weighted Average Remaining Contractual Term In Years Granted
WeightedAverageRemainingContractualTermInYearsGranted
P9Y8M12D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7112 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.81
icct Weighted Average Remaining Contractual Term In Years Forfeited
WeightedAverageRemainingContractualTermInYearsForfeited
P7Y9M18D
icct Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEnding
5869457 shares
icct Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding
2.79
icct Weighted Average Remaining Contractual Term In Years Ending
WeightedAverageRemainingContractualTermInYearsEnding
P9Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4285364 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y4M24D
icct Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Beginning
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesBeginning
395072 shares
icct Weighted Average Grant Date Fair Value Nonvested Beginning
WeightedAverageGrantDateFairValueNonvestedBeginning
3.76
icct Weighted Average Remaining Years To Vest Nonvested Begining
WeightedAverageRemainingYearsToVestNonvestedBegining
P8Y
icct Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Granted Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsGrantedNumberOfShares
5100241 shares
icct Weighted Average Grant Date Fair Values Nonvested Granted
WeightedAverageGrantDateFairValuesNonvestedGranted
2.64
icct Weighted Average Remaining Years To Vest Nonvested Granted
WeightedAverageRemainingYearsToVestNonvestedGranted
P9Y8M12D
icct Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsVestedNumberOfShares
-4285364 shares
icct Weighted Average Grant Date Fair Value Nonvested Vested
WeightedAverageGrantDateFairValueNonvestedVested
3.18
icct Weighted Average Remaining Years To Vest Nonvested Ending
WeightedAverageRemainingYearsToVestNonvestedEnding
P9Y4M24D
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
102208 usd
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
233651 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
icct Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginning
776328 shares
icct Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning
3.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5100241 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.64
icct Weighted Average Remaining Contractual Term In Years Granted
WeightedAverageRemainingContractualTermInYearsGranted
P9Y8M12D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7112 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.81
icct Weighted Average Remaining Contractual Term In Years Forfeited
WeightedAverageRemainingContractualTermInYearsForfeited
P7Y9M18D
icct Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEnding
5869457 shares
icct Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding
2.79
icct Weighted Average Remaining Contractual Term In Years Ending
WeightedAverageRemainingContractualTermInYearsEnding
P9Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4285364 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y4M24D
icct Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Beginning
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesBeginning
395072 shares
icct Weighted Average Grant Date Fair Value Nonvested Beginning
WeightedAverageGrantDateFairValueNonvestedBeginning
3.76
icct Weighted Average Remaining Years To Vest Nonvested Begining
WeightedAverageRemainingYearsToVestNonvestedBegining
P8Y
icct Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Granted Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsGrantedNumberOfShares
5100241 shares
icct Weighted Average Grant Date Fair Values Nonvested Granted
WeightedAverageGrantDateFairValuesNonvestedGranted
2.64
icct Weighted Average Remaining Years To Vest Nonvested Granted
WeightedAverageRemainingYearsToVestNonvestedGranted
P9Y8M12D
icct Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsVestedNumberOfShares
-4285364 shares
icct Weighted Average Grant Date Fair Value Nonvested Vested
WeightedAverageGrantDateFairValueNonvestedVested
3.18
icct Weighted Average Remaining Years To Vest Nonvested Ending
WeightedAverageRemainingYearsToVestNonvestedEnding
P9Y4M24D
icct Weighted Average Grant Date Fair Values Nonvested Forfeited Expired
WeightedAverageGrantDateFairValuesNonvestedForfeitedExpired
0
icct Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Ending
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesEnding
1209949 shares
icct Weighted Average Grant Date Fair Values Nonvested Ending
WeightedAverageGrantDateFairValuesNonvestedEnding
1.72
icct Weighted Average Remaining Years To Vest Nonvested Vested
WeightedAverageRemainingYearsToVestNonvestedVested
P9Y4M24D
us-gaap Restricted Stock Expense
RestrictedStockExpense
200000 usd
us-gaap Restricted Stock Expense
RestrictedStockExpense
184167 usd
icct Warrants To Be Issued Additional
WarrantsToBeIssuedAdditional
69000 shares
icct Number Of Warrants Outstanding Beginning
NumberOfWarrantsOutstandingBeginning
45129 shares
icct Weighted Average Exercise Price Of Warrants Beginning
WeightedAverageExercisePriceOfWarrantsBeginning
2.09
icct Weighted Average Remaining Life Of Warrants In Years Beginning
WeightedAverageRemainingLifeOfWarrantsInYearsBeginning
P4Y9M21D
icct Aggregate Intrinsic Value Of Warrants Beginning
AggregateIntrinsicValueOfWarrantsBeginning
0 usd
icct Number Of Warrants Granted
NumberOfWarrantsGranted
69000 shares
icct Weighted Average Exercise Price Of Warrants Granted
WeightedAverageExercisePriceOfWarrantsGranted
1.36
icct Weighted Average Remaining Life Of Warrants In Years Granted
WeightedAverageRemainingLifeOfWarrantsInYearsGranted
P4Y6M3D
icct Weighted Average Exercise Price Of Warrants Exercised
WeightedAverageExercisePriceOfWarrantsExercised
0
icct Weighted Average Exercise Price Of Warrants Cancelled
WeightedAverageExercisePriceOfWarrantsCancelled
0
icct Number Of Warrants Outstanding Ending
NumberOfWarrantsOutstandingEnding
114129 shares
icct Weighted Average Exercise Price Of Warrants Ending
WeightedAverageExercisePriceOfWarrantsEnding
1.65
icct Aggregate Intrinsic Value Of Warrants Ending
AggregateIntrinsicValueOfWarrantsEnding
0 usd
icct One Number Of Warrants Outstanding Beginning
OneNumberOfWarrantsOutstandingBeginning
425800 shares
icct One Weighted Average Exercise Price Of Warrants Beginning
OneWeightedAverageExercisePriceOfWarrantsBeginning
2.00
icct One Weighted Average Remaining Life Of Warrants In Years Beginning
OneWeightedAverageRemainingLifeOfWarrantsInYearsBeginning
P9Y8M12D
icct One Weighted Average Exercise Price Of Warrants Granted
OneWeightedAverageExercisePriceOfWarrantsGranted
0
icct One Weighted Average Exercise Price Of Warrants Exercised
OneWeightedAverageExercisePriceOfWarrantsExercised
0
icct One Weighted Average Exercise Price Of Warrants Expired
OneWeightedAverageExercisePriceOfWarrantsExpired
0
icct One Number Of Warrants Outstanding Ending
OneNumberOfWarrantsOutstandingEnding
425800 shares
icct One Weighted Average Exercise Price Of Warrants Ending
OneWeightedAverageExercisePriceOfWarrantsEnding
2.00
icct One Weighted Average Remaining Life Of Warrants In Years Ending
OneWeightedAverageRemainingLifeOfWarrantsInYearsEnding
P9Y2M12D
icct Two Preferred Stock Warrants Outstanding Beginning
TwoPreferredStockWarrantsOutstandingBeginning
10122313 shares
icct Weighted Average Grant Date Fair Values Nonvested Forfeited Expired
WeightedAverageGrantDateFairValuesNonvestedForfeitedExpired
0
icct Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Ending
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesEnding
1209949 shares
icct Weighted Average Grant Date Fair Values Nonvested Ending
WeightedAverageGrantDateFairValuesNonvestedEnding
1.72
icct Weighted Average Remaining Years To Vest Nonvested Vested
WeightedAverageRemainingYearsToVestNonvestedVested
P9Y4M24D
us-gaap Restricted Stock Expense
RestrictedStockExpense
200000 usd
us-gaap Restricted Stock Expense
RestrictedStockExpense
184167 usd
icct Warrants To Be Issued Additional
WarrantsToBeIssuedAdditional
69000 shares
icct Number Of Warrants Outstanding Beginning
NumberOfWarrantsOutstandingBeginning
45129 shares
icct Weighted Average Exercise Price Of Warrants Beginning
WeightedAverageExercisePriceOfWarrantsBeginning
2.09
icct Weighted Average Remaining Life Of Warrants In Years Beginning
WeightedAverageRemainingLifeOfWarrantsInYearsBeginning
P4Y9M21D
icct Aggregate Intrinsic Value Of Warrants Beginning
AggregateIntrinsicValueOfWarrantsBeginning
0 usd
icct Number Of Warrants Granted
NumberOfWarrantsGranted
69000 shares
icct Weighted Average Exercise Price Of Warrants Granted
WeightedAverageExercisePriceOfWarrantsGranted
1.36
icct Weighted Average Remaining Life Of Warrants In Years Granted
WeightedAverageRemainingLifeOfWarrantsInYearsGranted
P4Y6M3D
icct Weighted Average Exercise Price Of Warrants Exercised
WeightedAverageExercisePriceOfWarrantsExercised
0
icct Weighted Average Exercise Price Of Warrants Cancelled
WeightedAverageExercisePriceOfWarrantsCancelled
0
icct Number Of Warrants Outstanding Ending
NumberOfWarrantsOutstandingEnding
114129 shares
icct Weighted Average Exercise Price Of Warrants Ending
WeightedAverageExercisePriceOfWarrantsEnding
1.65
icct Weighted Average Remaining Life Of Warrants In Years Ending
WeightedAverageRemainingLifeOfWarrantsInYearsEnding
P4Y5M4D
icct Aggregate Intrinsic Value Of Warrants Ending
AggregateIntrinsicValueOfWarrantsEnding
0 usd
icct One Number Of Warrants Outstanding Beginning
OneNumberOfWarrantsOutstandingBeginning
425800 shares
icct One Weighted Average Exercise Price Of Warrants Beginning
OneWeightedAverageExercisePriceOfWarrantsBeginning
2.00
icct One Weighted Average Remaining Life Of Warrants In Years Beginning
OneWeightedAverageRemainingLifeOfWarrantsInYearsBeginning
P9Y8M12D
icct One Weighted Average Exercise Price Of Warrants Granted
OneWeightedAverageExercisePriceOfWarrantsGranted
0
icct One Weighted Average Exercise Price Of Warrants Exercised
OneWeightedAverageExercisePriceOfWarrantsExercised
0
icct One Weighted Average Exercise Price Of Warrants Expired
OneWeightedAverageExercisePriceOfWarrantsExpired
0
icct One Number Of Warrants Outstanding Ending
OneNumberOfWarrantsOutstandingEnding
425800 shares
icct One Weighted Average Exercise Price Of Warrants Ending
OneWeightedAverageExercisePriceOfWarrantsEnding
2.00
icct One Weighted Average Remaining Life Of Warrants In Years Ending
OneWeightedAverageRemainingLifeOfWarrantsInYearsEnding
P9Y2M12D
icct Two Preferred Stock Warrants Outstanding Beginning
TwoPreferredStockWarrantsOutstandingBeginning
10122313 shares
icct Two Weightedaverageexercisepriceofwarrantsbeginning
TwoWeightedaverageexercisepriceofwarrantsbeginning
11.50
icct One Weighted Average Remaining Life Of Warrant In Years Beginning
OneWeightedAverageRemainingLifeOfWarrantInYearsBeginning
P9Y8M12D
icct Two Weightedaverageexercisepriceofwarrantsgranted
TwoWeightedaverageexercisepriceofwarrantsgranted
0
icct Two Weightedaverageexercisepriceofwarrantsexercised
TwoWeightedaverageexercisepriceofwarrantsexercised
0
icct Two Weightedaverageexercisepriceofwarrantsexpired
TwoWeightedaverageexercisepriceofwarrantsexpired
0
icct Two Number Of Warrants Outstanding Ending
TwoNumberOfWarrantsOutstandingEnding
10122313 shares
icct Two Weightedaverageexercisepriceofwarrantsending
TwoWeightedaverageexercisepriceofwarrantsending
11.50
icct One Weighted Average Remaining Life Of Warrants In Years Ending Balance
OneWeightedAverageRemainingLifeOfWarrantsInYearsEndingBalance
P9Y2M12D
icct Three Preferred Stock Warrants Outstanding Beginning
ThreePreferredStockWarrantsOutstandingBeginning
1000000 shares
icct Three Weightedaverageexercisepriceofwarrantsbeginning
ThreeWeightedaverageexercisepriceofwarrantsbeginning
15.00
icct Three Weighted Average Remaining Life Of Warrants In Years Beginning
ThreeWeightedAverageRemainingLifeOfWarrantsInYearsBeginning
P9Y8M12D
icct Three Weightedaverageexercisepriceofwarrantsgranted
ThreeWeightedaverageexercisepriceofwarrantsgranted
0
icct Three Weightedaverageexercisepriceofwarrantsexercised
ThreeWeightedaverageexercisepriceofwarrantsexercised
0
icct Three Weightedaverageexercisepriceofwarrantsexpired
ThreeWeightedaverageexercisepriceofwarrantsexpired
0
icct Three Number Of Warrants Outstanding Ending
ThreeNumberOfWarrantsOutstandingEnding
1000000 shares
icct Three Weightedaverageexercisepriceofwarrantsending
ThreeWeightedaverageexercisepriceofwarrantsending
15.00
icct Three Weighted Average Remaining Life Of Warrants In Years Ending
ThreeWeightedAverageRemainingLifeOfWarrantsInYearsEnding
P9Y2M12D
icct Common Stock Issued Shares
CommonStockIssuedShares
291259 shares
icct Common Stock Issued Value
CommonStockIssuedValue
600000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1008376 usd
CY2024Q2 us-gaap Other Commitment
OtherCommitment
1326612 usd
icct Two Weightedaverageexercisepriceofwarrantsbeginning
TwoWeightedaverageexercisepriceofwarrantsbeginning
11.50
icct One Weighted Average Remaining Life Of Warrant In Years Beginning
OneWeightedAverageRemainingLifeOfWarrantInYearsBeginning
P9Y8M12D
icct Two Weightedaverageexercisepriceofwarrantsgranted
TwoWeightedaverageexercisepriceofwarrantsgranted
0
icct Two Weightedaverageexercisepriceofwarrantsexercised
TwoWeightedaverageexercisepriceofwarrantsexercised
0
icct Two Weightedaverageexercisepriceofwarrantsexpired
TwoWeightedaverageexercisepriceofwarrantsexpired
0
icct Two Number Of Warrants Outstanding Ending
TwoNumberOfWarrantsOutstandingEnding
10122313 shares
icct Two Weightedaverageexercisepriceofwarrantsending
TwoWeightedaverageexercisepriceofwarrantsending
11.50
icct One Weighted Average Remaining Life Of Warrants In Years Ending Balance
OneWeightedAverageRemainingLifeOfWarrantsInYearsEndingBalance
P9Y2M12D
icct Three Preferred Stock Warrants Outstanding Beginning
ThreePreferredStockWarrantsOutstandingBeginning
1000000 shares
icct Three Weightedaverageexercisepriceofwarrantsbeginning
ThreeWeightedaverageexercisepriceofwarrantsbeginning
15.00
icct Three Weighted Average Remaining Life Of Warrants In Years Beginning
ThreeWeightedAverageRemainingLifeOfWarrantsInYearsBeginning
P9Y8M12D
icct Three Weightedaverageexercisepriceofwarrantsgranted
ThreeWeightedaverageexercisepriceofwarrantsgranted
0
icct Three Weightedaverageexercisepriceofwarrantsexercised
ThreeWeightedaverageexercisepriceofwarrantsexercised
0
icct Three Weightedaverageexercisepriceofwarrantsexpired
ThreeWeightedaverageexercisepriceofwarrantsexpired
0
icct Three Number Of Warrants Outstanding Ending
ThreeNumberOfWarrantsOutstandingEnding
1000000 shares
icct Three Weightedaverageexercisepriceofwarrantsending
ThreeWeightedaverageexercisepriceofwarrantsending
15.00
icct Three Weighted Average Remaining Life Of Warrants In Years Ending
ThreeWeightedAverageRemainingLifeOfWarrantsInYearsEnding
P9Y2M12D
icct Common Stock Issued Shares
CommonStockIssuedShares
291259 shares
icct Common Stock Issued Value
CommonStockIssuedValue
600000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1008376 usd
CY2024Q2 us-gaap Other Commitment
OtherCommitment
1326612 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q1 us-gaap Registration Payment Arrangement Maximum Potential Consideration
RegistrationPaymentArrangementMaximumPotentialConsideration
5300000 usd
CY2024Q1 us-gaap Registration Payment Arrangement Maximum Potential Consideration
RegistrationPaymentArrangementMaximumPotentialConsideration
1210000 usd
CY2024Q1 us-gaap Registration Payment Arrangement Maximum Potential Consideration
RegistrationPaymentArrangementMaximumPotentialConsideration
700000 usd
CY2024Q1 us-gaap Cash
Cash
0 usd
CY2024Q1 us-gaap Cash
Cash
871 usd
CY2024Q1 us-gaap Cash
Cash
12752 usd
CY2024Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
959 usd
CY2024Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
54259 usd
CY2024Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2024Q1 us-gaap Real Estate Acquired Through Foreclosure
RealEstateAcquiredThroughForeclosure
5299041 usd
CY2024Q1 us-gaap Real Estate Acquired Through Foreclosure
RealEstateAcquiredThroughForeclosure
1154870 usd
CY2024Q1 us-gaap Real Estate Acquired Through Foreclosure
RealEstateAcquiredThroughForeclosure
678548 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
0 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
0 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
8700 usd
CY2024Q1 us-gaap Acquired Finite Lived Intangible Asset Residual Value
AcquiredFiniteLivedIntangibleAssetResidualValue
5300000 usd
CY2024Q1 us-gaap Acquired Finite Lived Intangible Asset Residual Value
AcquiredFiniteLivedIntangibleAssetResidualValue
1210000 usd
CY2024Q1 us-gaap Acquired Finite Lived Intangible Asset Residual Value
AcquiredFiniteLivedIntangibleAssetResidualValue
700000 usd
CY2024Q1 us-gaap Registration Payment Arrangement Maximum Potential Consideration
RegistrationPaymentArrangementMaximumPotentialConsideration
5300000 usd
CY2024Q1 us-gaap Registration Payment Arrangement Maximum Potential Consideration
RegistrationPaymentArrangementMaximumPotentialConsideration
1210000 usd
CY2024Q1 us-gaap Registration Payment Arrangement Maximum Potential Consideration
RegistrationPaymentArrangementMaximumPotentialConsideration
700000 usd
CY2024Q1 us-gaap Cash
Cash
0 usd
CY2024Q1 us-gaap Cash
Cash
871 usd
CY2024Q1 us-gaap Cash
Cash
12752 usd
CY2024Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
959 usd
CY2024Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
54259 usd
CY2024Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2024Q1 us-gaap Real Estate Acquired Through Foreclosure
RealEstateAcquiredThroughForeclosure
5299041 usd
CY2024Q1 us-gaap Real Estate Acquired Through Foreclosure
RealEstateAcquiredThroughForeclosure
1154870 usd
CY2024Q1 us-gaap Real Estate Acquired Through Foreclosure
RealEstateAcquiredThroughForeclosure
678548 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
0 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
0 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
8700 usd
CY2024Q1 us-gaap Acquired Finite Lived Intangible Asset Residual Value
AcquiredFiniteLivedIntangibleAssetResidualValue
5300000 usd
CY2024Q1 us-gaap Acquired Finite Lived Intangible Asset Residual Value
AcquiredFiniteLivedIntangibleAssetResidualValue
1210000 usd
CY2024Q1 us-gaap Acquired Finite Lived Intangible Asset Residual Value
AcquiredFiniteLivedIntangibleAssetResidualValue
700000 usd

Files In Submission

Name View Source Status
0001477932-24-005038-index-headers.html Edgar Link pending
0001477932-24-005038-index.html Edgar Link pending
0001477932-24-005038.txt Edgar Link pending
0001477932-24-005038-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
icct-20240630.xsd Edgar Link pending
icct_10q.htm Edgar Link pending
icct_ex311.htm Edgar Link pending
icct_ex312.htm Edgar Link pending
icct_ex321.htm Edgar Link pending
icct_ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
icct-20240630_def.xml Edgar Link unprocessable
icct-20240630_cal.xml Edgar Link unprocessable
icct-20240630_lab.xml Edgar Link unprocessable
icct-20240630_pre.xml Edgar Link unprocessable
icct_10q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable